Page 153 - Read Online

Page 16 of 17 Chen et al. Hepatoma Res 2019;5:12 I http://dx.doi.org/10.20517/2394-5079.2019.03

and effectiveness. Chin J Oncol 2017;39:946-51. (in Chinese)
98. Bureau of Disease Control of National Health Commission of PR China, China Cancer Foundation, Expert Committee on Rural
Cancer Project on Early Detection and Early Treatment. Project report on cancer early detection and early treatment (rural area): 2017-
2018. Beijing: People’s Medical House Press; 2018. pp. 26-30. (in Chinese)
99. Breau of Disease Control of National Health Commission of PR China. Technical Protocols for Early Diagnosis and Treatment of
Cancer in Huaihe River Basin. Available from: http://www.doc88.com/p-4334139219880.html. [Last accessed on 6 Jan 2019].
100. Dai M, Shi JF, Li N. Design and prospective target of the cancer screening program in Urban China. Chin J Prev Med 2013;47:179-82.
(in Chinese)
101. Qiu WQ, Shi JF, Guo LW, Mao AY, Huang HY, et al. Medical expenditure for liver cancer in urban China: a 10-year multicenter
retrospective survey (2002-2011). J Can Res Ther 2018;14:163-70.
102. Ji M, Liu Z, Chang ET, Yu X, Wu B, et al. Mass screening for liver cancer: results from a demonstration screening project in
Zhongshan City, China. Sci Rep 2018;8:12787.
103. Sherman M, Bruix J. Screening for liver cancer: the rush to judgment. Ann Intern Med 2012;157:300-1; author reply 301-2.
104. Kansagara D, Papak J, Pasha AS, O’Neil M, Freeman M, et al. Screening for hepatocellular carcinoma in chronic liver disease: a
systematic review. Ann Intern Med 2014;161:261-9.
105. Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update.
Hepatology 2011;53:1020-2.
106. Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, et al. Management of hepatocellular carcinoma in Asia: consensus statement
from the Asian Oncology Summit 2009. Lancet Oncol 2009;10:1111-8.
107. Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, et al. Hepatocellular carcinoma (HCC): a global perspective. J Clin
Gastroenterol 2010;44:239-45.
108. European Association for the Study of the Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC
clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43.
109. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, et al. Management of hepatocellular carcinoma in Japan: consensus-based
clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011;29:339-64.
110. Zhou J, Sun HC, Wang Z, Cong WM, Wang JH, et al. Guidelines for diagnosis and treatment of primary liver cancer in China (2017
edition). Liver Cancer 2018;7:235-60.
111. Sharma P, Saini SD, Kuhn LB, Rubenstein JH, Pardi DS, et al. Knowledge of hepatocellular carcinoma screening guidelines and
clinical practices among gastroenterologists. Dig Dis Sci 2011;56:569-77.
112. Lederle FA, Pocha C. Screening for liver cancer: the rush to judgment. Ann Intern Med 2012;156:387-9.
113. Kerry SM, Bland JM. Analysis of a trial randomised in clusters. BMJ 1998;316:54.
114. Petruzziello A. Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Related Hepatocellular Carcinoma. Open
Virol J 2018;12:26-32.
115. Law M. Screening without evidence of efficacy. BMJ 2004;328:301-2.
116. Moon AM, Weiss NS, Beste LA, Su F, Ho SB, et al. No association between screening for hepatocellular carcinoma and reduced
cancer-related mortality in patients with cirrhosis. Gastroenterology 2018;155:1128-39.e6.
117. Lersritwimanmaen P, Nimanong S. Hepatocellular carcinoma surveillance: benefit of serum alfa-fetoprotein in real-world practice.
Euroasian J Hepatogastroenterol 2018;8:83-7.
118. Poustchi H, Farrell GC, Strasser SI, Lee AU, McCaughan GW, et al. Feasibility of conducting a randomized control trial for liver
cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed ? Hepatology 2011;54:1998-2004.
119. Trevisani F1, D’Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular
carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001;34:570-5.
120. Aghoram R, Cai P, Dickinson JA. Alpha-foetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in
patients with chronic hepatitis B. Cochrane Database Syst Rev 2012;CD002799.
121. Sherman M. Alphafetoprotein: an obituary. J Hepatol 2001;34:603-5.
122. Sherman M. Serological surveillance for hepatocellular carcinoma: time to quit. J Hepatol 2010;52:614-5.
123. Forner A, Reig M, Bruix J. Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star. Gastroenterology
2009;137:26-9.
124. Cole P, Morrison AS. Basic issues in population screening for cancer. J Natl Cancer Inst 1980;64:1263-72.
125. Prorok PC. Epidemiologic approach for cancer screening. Problems in design and analysis of trials. Am J Pediatr Hematol Oncol
1992;14:117-28.
126. Fong ZV, Tanabe KK. The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive
and evidence-based comparison and review. Cancer 2014;120:2824-38.
127. Cancer Research UK. Liver cancer. 2016. Available from: http://www.cancerresearchuk.org/about-cancer/liver-cancer/getting-
diagnosed/screening. [Last accessed on 20 Dec 2018]
128. Simonetti J, Bulkow L, McMahon BJ, Homan C, Snowball M, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular
carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010;51:1531-7.
129. Kumar A. Current practices in management of hepatocellular carcinoma in India: results of an online survey. J Clin Exp Hepatol
2014;4:S140-6.
130. Eltabbakh M, Zaghla H, Abdel-Razek W, Elshinnawy H, Ezzat S, et al. Utility and cost-effectiveness of screening for hepatocellular
carcinoma in a resource-limited setting. Med Oncol 2015;32:432.
131. Ayuso C, Rimola J, Vilana R, Burrel M, Darnell A, et al. Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines.
Eur J Radiol 2018;101:72-81.